Cécile Dorange

Showing 1-12 of 12 articles

The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled

Abizaid A, Costa Jr J, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong W-F, Sudhir K, Serruys P

April 20, 2015 | 10.4244/EIJV10I12A243

Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial

Bourantas C, Farooq V, Zhang Y-J, Muramatsu T, Gogas B, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia H, Serruys P

March 20, 2015 | 10.4244/EIJY14M04_11

Procedural and clinical outcomes of the Absorb everolimus-eluting bioresorbable vascular scaffold: one-month results of the Bioresorbable vascular Scaffold Evaluated At Rotterdam Cardiology Hospitals (B-SEARCH)

Simsek C, Magro M, Onuma Y, Boersma E, Smits P, Dorange C, Veldhof S, Regar E, Serruys P, van Geuns R

June 20, 2014 | 10.4244/EIJV10I2A38

Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months

Serruys P, Onuma Y, Garcia-Garcia H, Muramatsu T, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Smits P, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert K, Rapoza R, Ormiston J

March 20, 2014 | 10.4244/EIJV9I11A217

The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials

Gogas B, Bourantas C, Garcia-Garcia H, Onuma Y, Muramatsu T, Farooq V, Diletti R, van Geuns R, De Bruyne B, Chevalier B, Thuesen L, Smits P, Dudek D, Koolen J, Windecker S, Whitbourn R, McClean D, Dorange C, Miquel-Hebert K, Veldhof S, Rapoza R, Ormiston J, Serruys P

October 25, 2013 | 10.4244/EIJV9I6A115

Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study

Gomez-Lara J, Diletti R, Brugaletta S, Onuma Y, Farooq V, Thuesen L, McClean D, Koolen J, Ormiston J, Windecker S, Whitbourn R, Dudek D, Dorange C, Veldhof S, Rapoza R, Regar E, Garcia-Garcia H, Serruys P

June 27, 2012

Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology study

Brugaletta S, Garcia-Garcia H, Diletti R, Gomez-Lara J, Garg S, Onuma Y, Shin E, van Geuns R, De Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Dorange C, Veldhof S, Rapoza R, Sudhir K, Bruining N, Ormiston J, Serruys P

April 20, 2011

Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial

Khattab A, Richardt G, Verin V, Kelbæk H, Macaya C, Berland J, Miquel-Hebert K, Dorange C, Serruys P

March 20, 2008

One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with <i>de novo</i> native coronary artery lesions: the SPIRIT II study

Ruygrok P, Desaga M, Van den Branden B, Rasmussen K, Suryapranata H, Dorange C, Veldhof S, Serruys P

November 20, 2007

Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial)

Beijk M, Neumann F, Wiemer M, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys P, Piek J

August 20, 2007

Prospective non-randomized multi-center evaluation of the non-polymer based ACHIEVE™ Paclitaxel Eluting Coronary Stent System in treatment of lesions with high risk of revascularization due to restenosis: the DELIVER II study

Grube E, Gershlick A, Bartorelli A, Buellesfeld L, Blanchard D, Macaya C, Buettner H, Lim V, Boone E, Dorange C, Marco J

February 20, 2006

One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings<br />(The SPIRIT FIRST Trial)

Tsuchida K, Piek J, Neumann F, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Veldhof S, Dorange C, Serruys P

November 20, 2005

1

Latest news

CTOs, next-day discharge after TAVI, ViV, cerebral embolic protection, TMVR

Ahead of Print: Coronary Artery Thrombosis in COVID-19

Coronary collaterals, the natural grafts of CTO lesions

TICAKOREA, PEPCAD NSTEMI, CROSS-AMI, PARTNER-2A 5 years, and more

(The Trials book is supported by Biotronik)

Guidance Papers

Guidelines, consensus & position papers

Intravascular ultrasound in PCI for in-stent CTO: guidance for long-term success

JM De la Torre Hernandez

This Week's JAA's: Real-world Use of the Evolut PRO Valve...

Valvular disease